Article

Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women

Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, People's Republic of China.
Tumor Biology (Impact Factor: 3.61). 04/2011; 32(4):713-9. DOI: 10.1007/s13277-011-0172-7
Source: PubMed

ABSTRACT

Basal-like breast cancer (BLBC) appears to be characterized by a relatively unfavorable prognosis and lack of a specific therapeutic target. Estrogen receptor-alpha (ERα) has been widely accepted as a prognostic marker and a predictor for endocrine therapy response of breast cancer. This study aimed to clarify the correlation of ERα methylation with the pathogenesis and clinicopathological significance of sporadic BLBC of Chinese women without a family history of the cancer. The methylation of ERα promoter was investigated in genomic DNA of 60 sporadic BLBC with 108 cases of non-BLBC as control by methylation-specific polymerase chain reaction. We also investigated the expression of p53, breast cancer gene (BRCA)-1, and BRCA-2 by immunohistochemistry and analyzed the correlation between ERα methylation and clinicopathological features of BLBC. ERα methylation was observed in 48 of 60 (80.0%) sporadic BLBC, which was significantly higher than in sporadic non-BLBC cancer (47/108, 43.5%; χ2=20.89, p<0.01). No correlation was found between the ERα methylation and age and menopausal status, while it was significantly associated with lymph node metastasis, tumor stage, nuclear p53 accumulation, and BRCA-1 and BRCA-2 expression in sporadic BLBC. The ERα methylation status in basal-like breast cancer was significantly higher than in sporadic non-basal-like breast cancer. It was associated with the lymph node metastasis, tumor stage, p53 nuclear accumulation, and BRCA-1 and BRCA-2 expression in BLBC. It may play an important role in BLBC pathogenesis.

0 Followers
 · 
6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is the leading cause of malignancy in women in the Western world. Inactivating mutations in tumor suppressor genes, gain-of-function mutations in oncogenes, and changes in DNA copy number result in the initiation, abnormal growth, resistance to drug treatment, and spread of breast tumors. In addition, epigenetic alterations across the genome play a critical role in carcinogenesis of the breast. Here we discuss key epigenetic events including hyper- and hypomethylation of CpG islands, chromatin remodeling, nuclear localization of genes, chromatin loops, and differential expression of small noncoding RNAs as they relate to the normal development of the breast and how their abnormal regulation leads to initiation, progression, and metastasis. This chapter not only highlights the role of epigenetics during normal breast development but also outlines basic epigenetic processes which are perturbed during the development of breast cancer. In addition, the role of epigenetics in classifying breast cancers, in determining prognosis, and as potential therapeutic targets will be discussed. As technologies for interrogating the entire genome improve, the importance of epigenetic dysregulation in breast cancer carcinogenesis is becoming more evident. © 2012 Springer Science+Business Media New York. All rights are reserved.
    No preview · Chapter · Jan 2012
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis tumor antigen 1 (MTA1), a novel candidate metastasis-associated gene, is known to increase the migration and invasion of various tumor cells in vitro. It also plays an important role in tumorigenesis and tumor aggressiveness of breast cancer. Estrogen receptor alpha (ERα) plays an important role in the etiology of breast cancer and has been widely accepted as a prognostic marker for breast cancer and a response predictor for endocrine therapy. The ERα gene methylation has been linked to the lack of ERα expression in breast cancer. The aim of the study is to assess the correlation between the ERα methylation and MTA1 expression in breast cancer and further to investigate whether the repressed ERα methylation can downregulate the expression of MTA1 in vitro. In general, we found ERα methylation had significant correlation with the MTA1 expression (p < 0.05) in female patients of breast cancer (n = 102) by methylation-specific polymerase chain reaction and immunohistochemistry. To gain a deeper insight into the molecular mechanism underlying the relation between MTA1 and ERα methylation, we treated the invasive breast cancer cell lines with the demethylating agent, found the downregulation of MTA1 protein expression, and mRNA with the unmethylation of ERα (p < 0.05). And the invasive ability of breast cancer cells was significantly positively associated with MTA1 expression. These unique findings have greatly extended our current knowledge about the relation between ERα methylation and MTA1 expression. These data strongly support the hypothesis that methylation is involved in the relation between MTA1 and ERα in breast cancer.
    No preview · Article · May 2012 · Tumor Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over two-thirds of breast cancers rely on estrogen receptor α (ERα) for their growth. Endocrine therapies antagonize estrogen-dependent ERα activation but resistance to these treatments occurs and is associated with poor prognosis. Crosstalk between alternative survival pathways and ERα are currently held as the primary cause of resistance. However, blocking these pathways does not cure endocrine therapy resistant breast cancer suggesting the existence of additional mechanisms. While cancer is commonly considered a genetic disease, the importance of epigenetic events in promoting tumor initiation and progression is increasingly recognized. Here, we consider how epigenetic modifications and alterations to the chromatin landscape contribute to endocrine therapy resistance by modulating ERα expression or altering its genomic activity.
    No preview · Article · Dec 2012 · Epigenomics
Show more